Skip to main content

News


If you want to be in the know about what’s going on at our organization, you’ve come to the right place!

Be sure to check back regularly to get our latest news updates.


NHF will update this page as more statements become available.

Industry Forms Alliance to Develop Potential Treatment for Patients with Serious COVID-19 Complicati

Developing such a treatment would necessitate plasma donations from many people who have fully recovered from COVID-19, and whose blood contains antibodies that can fight the coronavirus.

Comment Period for VWD Clinical Practice Guidelines Open

NHF is seeking comments on draft ASH ISTH NHF WHF clinical practice guidelines on VWD Diagnosis & Management.

APLUS Statement on FDA Policy Changes Related to Blood and Plasma Donation

NHF and HFA are members of the American Plasma Users Coalition.

The FDA approval is for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors.

What you need to know about access to HTCs

Supplemental MASAC Statement Regarding Home Delivery and Refill Under State of Emergency Declaration

Having an adequate supply of treatment products at home is critical to achieve safe patient care and continuity of treatment.

Town Hall Webinar - Insurance: Coping During COVID-19

On March 27th, experts from NHF answered your questions regarding changes in insurance in our townhall webinar: Insurance: Coping During COVID-19.

MASAC's latest set of recommendations cover the use and management of emicizumab, the latest products licensed to treat bleeding disorders, integrating the CDC's opioid prescribing guidelines into bleeding disorders care, and bleeding prophylaxis for patients undergoing gastrointestinal endoscopies. 

Dr. Valentino's COVID-19 Town Hall Webinar

On March 20th, NHF’s President and CEO answered your questions about how COVID-19 affects our community.

Health and Wellness Update from Dr. Valentino

Information and techniques you and your family can use to stay healthy during the COVID-19 pandemic.

NHF-HFA insurance question logo

Do you have questions regarding insurance coverage in light of the COVID-19 pandemic? We're here to help.

The halted trials were investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status.

NHF will update this page as more statements about product supply becomes available.

Statement from Len Valentino on COVID-19

A statement from Dr. Valentino addressing the concerns of the community regarding the rapidly evolving COVID-19 situation.

2020 NYC Half Marathon Cancelled

The 2020 United Airlines Half Marathon has been cancelled due to concerns over transmission of COVID-19.

NHF Office Response to COVID-19

Due to the recommendations of local government, NHF's New York City staff will be working remotely until further notice. We will continue to work to serve the bleeding disorders community during this time.

Takeda Responds to HFA-NHF Letter on VONVENDI Recall

Takeda responded to the HFA-NHF letter late yesterday regarding the recall of two lots of VONVENDI von Willebrand factor.

NHF Letter to the Community on COVID-19

The National Hemophilia Foundation will continue to monitor the rapidly changing situation regarding COVID-19 and provide regular updates to our community.

XINITY® is currently indicated for the control and prevention of bleeding episodes and for perioperative management in adults and children, 12 years of age or older, with hemophilia B.

More than 400 people affected by bleeding disorders asked their legislators to take action on the Hemophilia SNF Access Act

MASAC Letter to the Community Regarding the Coronavirus Disease 2019 (COVID-19)

We will provide updated guidance if new information has implication for the bleeding disorders community.

Nationwide Children’s Hospital Looks at Optimal Dosing in the Emergency Department

On February 28th, Genentech released a statement relating to the supply of Hemlibra as it relates to 2019-nCoV (novel coronavirus).

Joint Statement on Recall of VONVENDI Lots

On February 27th, HFA and NHF submitted a letter to Takeda focusing on preliminary questions regarding the recall.

Bayer Releases New Statement onf Kogenate Recall

HFA and NHF recognize that recalls can be unsettling for many in the bleeding disorders community. We are in communications with Takeda to obtain additional detailed and timely information.